International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Janssen Initiates First-of-its-kind Clinical Study to Bridge Critical Gaps in Care for People of Color With Moderate to Severe Plaque Psoriasis

news_janssen blog image
More than 8 million Americans experience the physical, psychological, and emotional toll of psoriasis, but people of color experience additional challenges due to limited medical research, education, and underrepresentation in clinical studies. To help address these critical gaps, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the initiation of VISIBLE. VISIBLE is a first-of-its-kind, large-scale prospective clinical study dedicated to generating key disease insights among Black, Hispanic, Asian, Indigenous, and other people of color. This study reinforces Janssen’s commitments to inclusive clinical research and addressing health inequities.
Janssen J & J logo
Categories
Recent Posts
Lilly Press Release Graphic

Lilly Announces a New, Citrate-Free Formulation of Taltz® (ixekizumab)

Arcutis Press Release Graphic

Arcutis Announces FDA Approval for ZORYVE (Roflumilast) Cream 0.3% for Plaque Psoriasis in Individuals Age 12 and Older

2022_radlacongress_report

Un Enfoque en Psoriasis: Un Reporte de el Congreso RADLA 2022

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.